News

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed their thoughts on major moments in the past 25 years of cell and gene therapy research.

It was noted that the CA19-9 reductions in the 5 patients observed after infusion of satri-cel ranged from 51.3% to 96.1%.

In terms of safety, there were no AEs or serious AEs deemed related to AB-1002.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The IND application enabling the launch of the CELESTE trial in the US was previously cleared by the FDA in July 2025.

The primary end point of the study was met.

Review top news and interview highlights from the week ending October 17, 2025.

Headaches, falls, and nausea constituted the common treatment-emergent AEs, and were deemed mild-to-moderate in terms of severity.

The efficacy data included 4 patients who had discontinued their SOC therapy in a time frame of 4 to 11 weeks after being treated with FLT201.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Krystal is the second company to have received the new FDA designation.

The RDEA program is meant to support use of novel end points for measuring efficacy in clinical studies for therapies aimed at treating rare diseases.

The FDA has set the PDUFA action date for the BLA at March 28, 2026.

Pending talks with the FDA, Regeneron intends to submit a regulatory application for DB-OTO before the end of 2025.

With regard to safety, MYR-101 was characterized as “well tolerated” with a “favorable safety profile.”

Review top news and interview highlights from the week ending October 10, 2025.

Verismo emphasized that the milestone strengthens its relationship with the Institute for Follicular Lymphoma Innovation.

Neurogene also relayed new preclinical findings on the use of intracerebroventricular and intrathecal lumbar delivery of NGN-401.

AVB-114 previously received fast track designation from the FDA in February of this year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The PDUFA target action date for the BLA has been set at April 6, 2026.

The company cited strategic prioritization as the reason for its decision.

Taysha also announced that the FDA has aligned with the company on the pivotal trial protocol and statistical analysis plan.

Review top news and interview highlights from the week ending October 3, 2025.

UB-VV111 is currently being evaluated in a phase 1 clinical trial for adult patients with R/R CD19+ B-cell malignancies.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive® team.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.